The stock has a 36-month beta value of 0.12. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for GANX is 28.48M, and at present, short sellers hold a 1.02% of that float. On June 26, 2025, the average trading volume of GANX was 278.23K shares.
GANX) stock’s latest price update
Gain Therapeutics Inc (NASDAQ: GANX)’s stock price has soared by 8.94 in relation to previous closing price of 1.79. Nevertheless, the company has seen a gain of 14.04% in its stock price over the last five trading days. globenewswire.com reported 2025-06-10 that BETHESDA, Md., June 10, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO of Gain, will present at two upcoming investor conferences: H.C.
GANX’s Market Performance
Gain Therapeutics Inc (GANX) has seen a 14.04% rise in stock performance for the week, with a 8.33% gain in the past month and a -14.47% plunge in the past quarter. The volatility ratio for the week is 6.07%, and the volatility levels for the past 30 days are at 4.14% for GANX. The simple moving average for the past 20 days is 6.38% for GANX’s stock, with a -1.57% simple moving average for the past 200 days.
Analysts’ Opinion of GANX
Many brokerage firms have already submitted their reports for GANX stocks, with Scotiabank repeating the rating for GANX by listing it as a “Sector Outperform.” The predicted price for GANX in the upcoming period, according to Scotiabank is $12 based on the research report published on March 07, 2025 of the current year 2025.
ROTH MKM, on the other hand, stated in their research note that they expect to see GANX reach a price target of $7. The rating they have provided for GANX stocks is “Buy” according to the report published on December 06th, 2024.
Oppenheimer gave a rating of “Outperform” to GANX, setting the target price at $8 in the report published on August 14th of the previous year.
GANX Trading at 4.19% from the 50-Day Moving Average
After a stumble in the market that brought GANX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.87% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GANX starting from Mack Gene, who purchase 14,400 shares at the price of $1.01 back on Aug 09 ’24. After this action, Mack Gene now owns 14,400 shares of Gain Therapeutics Inc, valued at $14,544 using the latest closing price.
Islam Khalid, the Executive Chairman of Gain Therapeutics Inc, purchase 50,000 shares at $1.00 during a trade that took place back on Aug 09 ’24, which means that Islam Khalid is holding 50,000 shares at $49,940 based on the most recent closing price.
Stock Fundamentals for GANX
The total capital return value is set at -3.08. Equity return is now at value -290.21, with -159.74 for asset returns.
Based on Gain Therapeutics Inc (GANX), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -106.6.
Currently, EBITDA for the company is -19.79 million with net debt to EBITDA at 0.44. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.22.
Conclusion
To sum up, Gain Therapeutics Inc (GANX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
